Prism Health North Texas
Dallas, Texas, United States
Disclosure(s): Abbvie: Advisor/Consultant, Grant/Research Support, Honoraria; Gilead Sciences, Inc.: Advisor/Consultant, Grant/Research Support; Janssen: Advisor/Consultant, Grant/Research Support, Honoraria; Merck: Advisor/Consultant, Grant/Research Support, Honoraria; Theratechnologies: Advisor/Consultant, Grant/Research Support, Honoraria; ViiV: Advisor/Consultant, Grant/Research Support, Honoraria
577 - Week 48 Results of a Phase 2 Study Evaluating Once-weekly Oral Islatravir Plus Lenacapavir
Saturday, October 19, 2024
2:09 PM – 2:21 PM US PT